Lipitor vs Leqvio: What to Do When One Fails

Why This Comparison Matters More for Women Than You Might Think

High LDL cholesterol is not a gender-neutral problem. Women tend to develop cardiovascular disease about a decade later than men, but that protection disappears quickly after menopause. Estrogen suppresses LDL-receptor degradation via PCSK9, so when estrogen falls during perimenopause, LDL can climb 10-15 mg/dL in just a few years. The timing of that rise often catches women off guard.

Atorvastatin is the drug most clinicians reach for first, and with good reason. The ASCOT-LLA trial demonstrated that atorvastatin 10 mg reduced major cardiovascular events by 36 percent versus placebo in people with hypertension and at least three other cardiovascular risk factors, including a meaningful proportion of women. But "fails" can mean two different things: you cannot tolerate the side effects, or you take it faithfully and still cannot reach your LDL target. Inclisiran addresses both failure modes, though in different ways.

This article walks through what each drug does, which women are best suited to each one, and how to think about switching, adding, or combining them across reproductive life stages.

How Each Drug Works: Different Mechanisms, Same Target

Atorvastatin: Blocking Cholesterol Synthesis

Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Lower intracellular cholesterol prompts liver cells to upregulate LDL receptors, which pulls more LDL out of circulation. At 40 mg daily it reduces LDL by roughly 41-50 percent; at 80 mg, reductions approach 55-60 percent.

One subtlety women often are not told: statin metabolism is sex-specific. Atorvastatin is primarily a CYP3A4 substrate. Women generally have lower CYP3A4 activity than men and higher subcutaneous fat mass relative to lean mass, producing higher plasma statin concentrations and a greater AUC for the same mg/kg dose. That pharmacokinetic difference may explain why women report myalgia and muscle toxicity at higher rates than men, even on identical doses.

Inclisiran: Silencing the Gene That Degrades LDL Receptors

Inclisiran works at the RNA level. It is a small interfering RNA (siRNA) conjugated to a triantennary GalNAc ligand that targets hepatocytes specifically. Once inside the cell, it silences PCSK9 mRNA, reducing production of the PCSK9 protein that would otherwise tag LDL receptors for destruction. Fewer PCSK9 molecules means more LDL receptors survive on the cell surface, so more LDL is cleared from blood.

The key practical difference: inclisiran is injected subcutaneously (in clinic, by a health-care provider) at day 1, day 90, and then every 6 months. After the loading sequence, plasma PCSK9 protein falls by approximately 70-80 percent and LDL by 50 percent from baseline, and that effect is sustained between injections because the gene silencing persists.

The Key Evidence: What the Trials Show

ASCOT-LLA and Atorvastatin in Women

The ASCOT-LLA trial published in The Lancet in 2003 enrolled 10,305 participants with hypertension. Women made up 19 percent of the cohort. Atorvastatin 10 mg reduced the primary endpoint (non-fatal MI plus fatal CHD) by 36 percent over a median 3.3 years. The trial was stopped early because the benefit was so clear, but the female-specific subgroup was underpowered. This is a documented evidence gap: most of the key statin trials enrolled predominantly male cohorts, and the cardiovascular benefit in women is often extrapolated rather than directly demonstrated at the same statistical confidence.

ORION-10 and ORION-11: Inclisiran in High-Risk Patients

The phase 3 ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020 enrolled 3,457 patients (ORION-10: established CVHD; ORION-11: CVHD or equivalent risk) already on maximally tolerated statins. Inclisiran reduced LDL by 51 percent in ORION-10 and 49 percent in ORION-11 compared with placebo at 510 days, with a consistent safety profile. Women represented approximately 26-28 percent of both trial populations. Sex-stratified analyses were not powered to detect differential outcomes, so female-specific cardiovascular endpoint data remains extrapolated from the pooled results.

A direct CVHD outcomes trial for inclisiran (ORION-4, ~15,000 participants) is ongoing; results are expected around 2026. Until those data land, inclisiran's effect on hard endpoints in women specifically is inferred from the LDL-reduction magnitude rather than directly proven.

A Framework for Women: When Atorvastatin Has "Failed"

Not every woman who is unhappy on atorvastatin has experienced a true failure. Distinguishing between the two categories below changes the next step completely.

Category 1: Intolerance (Side Effects)

The most common reason women stop atorvastatin is muscle-related symptoms, reported by up to 20 percent of women on high-intensity statin therapy compared with roughly 10-15 percent of men. Symptoms range from mild aching to, rarely, rhabdomyolysis. Other intolerance patterns include transaminase elevation, new-onset diabetes risk (higher in women with pre-existing insulin resistance or PCOS), and cognitive complaints that are reported more in women though causation remains unproven.

If intolerance is the issue, the first question is whether you can tolerate a lower dose of atorvastatin or an alternative statin (rosuvastatin, for example, has a different metabolic pathway and a more favorable muscle-side-effect profile in some women). Inclisiran can then be added to a low-dose statin to reach LDL targets without forcing you up to a dose you cannot handle.

Category 2: Insufficient LDL Lowering Despite Adherence

If you are taking atorvastatin 40-80 mg reliably and your LDL still sits above your individualized goal (typically <70 mg/dL for high-risk women, <55 mg/dL for very-high-risk by 2019 ESC/EAS guidelines), the next step depends on cardiovascular risk level. Adding ezetimibe (cheap, oral, ~18-20% additional LDL reduction) is usually the first add-on. If LDL still does not reach goal, inclisiran is a strong candidate because its ~50% additional reduction is the largest available from a single add-on agent.

How Lipid Physiology Shifts Across a Woman's Life

Reproductive Years (Ages 20-40)

LDL tends to be lower during reproductive years because circulating estrogen upregulates hepatic LDL receptors. Statins are rarely needed unless you have familial hypercholesterolemia (FH), PCOS-associated dyslipidemia, or premature cardiovascular disease. Women with FH have a 1-in-250 prevalence and are often diagnosed late; LDL >190 mg/dL without another cause should prompt genetic counseling.

Trying to Conceive

Both atorvastatin and inclisiran must be stopped before conception. See the dedicated pregnancy section below.

Perimenopause (Typically Ages 45-55, But Variable)

This is the highest-risk window for LDL to climb without obvious lifestyle cause. The transition usually spans 4-8 years. LDL rises as SHBG falls and estrogen fluctuates, and triglycerides may also increase by 10-25 percent during perimenopause. Starting atorvastatin in perimenopause for a woman whose 10-year ASCVD risk has crossed 7.5 percent is consistent with ACC/AHA 2019 cholesterol guideline recommendations.

Post-Menopause

After menopause, LDL typically stabilizes at a new, higher set point. This is also when adherence to a daily pill can become difficult in women managing multiple medications for bone health, blood pressure, or thyroid conditions. The twice-yearly injection schedule of inclisiran is a practical advantage in this group.

Women With PCOS

PCOS is associated with atherogenic dyslipidemia: low HDL, elevated triglycerides, small dense LDL, and insulin resistance. Statin therapy in PCOS requires awareness that statins may worsen insulin resistance slightly, and women with PCOS already carry a higher baseline risk of type 2 diabetes. Atorvastatin is still used and generally appropriate, but monitoring fasting glucose or HbA1c every 6-12 months is reasonable. Inclisiran has not been specifically studied in PCOS populations.

Pregnancy, Lactation, and Contraception: What You Must Know

This section applies directly if you are on either drug and considering pregnancy, are currently pregnant, or are breastfeeding.

Atorvastatin in Pregnancy

Atorvastatin is FDA-labeled as contraindicated in pregnancy. The concern is theoretical inhibition of cholesterol synthesis during fetal development, which depends on adequate cholesterol for neural myelination and cell membrane formation. Animal data showed skeletal malformations at supratherapeutic doses. Human data are limited, but current guidance is conservative: stop atorvastatin at least 1 month before attempting conception, and do not restart until breastfeeding is complete.

If you have familial hypercholesterolemia and need LDL lowering during pregnancy, LDL apheresis is the safest option for very-high-risk cases. Discuss with a lipid specialist before stopping your statin if FH is your diagnosis.

Inclisiran in Pregnancy

Inclisiran carries no human pregnancy data as of 2025. Animal reproductive toxicity studies showed adverse embryo-fetal outcomes at clinically relevant exposures. Because inclisiran is injected in clinic every 6 months, the drug cannot simply be "skipped" for one dose the way an oral medication can, since its gene-silencing effect persists for months after each injection. Women of reproductive age on inclisiran should use reliable contraception throughout treatment. If pregnancy is planned, discuss with your cardiologist or lipid specialist at least 6-12 months in advance, given the drug's long duration of action.

Lactation

Neither atorvastatin nor inclisiran has adequate human lactation data. Atorvastatin is lipophilic and likely transfers to breast milk to some degree. The manufacturer recommends against breastfeeding while taking it. Inclisiran lactation transfer is unknown. Avoiding both during breastfeeding is the conservative standard.

Contraception Requirement Summary

| Drug | Stop before conception | Safe in pregnancy | Safe in lactation | |---|---|---|---| | Atorvastatin | At least 1 month prior | No | No | | Inclisiran | 6-12 months prior (consult specialist) | No (no human data; animal harm) | Unknown; avoid |

Side Effects: A Woman-Centered Comparison

Atorvastatin Side Effects Specific to Women

Myalgia is the most reported side effect and women are at higher risk, particularly at high-intensity doses (40-80 mg). Risk factors in women include: small body size, hypothyroidism (common in perimenopausal women), CYP3A4 interactions with some antifungals and antibiotics, and possibly low vitamin D status. Statin-associated muscle symptoms occur in 5-20 percent of patients in real-world data, with the higher end disproportionately female.

New-onset diabetes is a class effect. Women with pre-existing insulin resistance, PCOS, gestational diabetes history, or a BMI >30 face a modestly higher absolute risk. The cardiovascular benefit still outweighs this risk in high-risk women, but it is worth monitoring.

Inclisiran Side Effects

The most common adverse event in ORION-10 and ORION-11 was injection-site reactions, occurring in approximately 8.2 percent of inclisiran recipients versus 1.8 percent with placebo. Reactions were mostly mild and transient. Inclisiran does not cause myalgia because it does not inhibit the mevalonate pathway in muscle tissue. For women who had to stop a statin because of muscle pain, this is a meaningful clinical difference.

No significant liver enzyme abnormalities, no new-onset diabetes signal, and no neurological adverse events above placebo rates have been observed in the available trial data.

Who This Is Right For (and Who It Is Not)

Women Who Should Consider Staying on Atorvastatin

You are well controlled on atorvastatin 20-40 mg with no side effects and your LDL is at goal. You are cost-sensitive: generic atorvastatin costs under $10 per month. You are in your reproductive years and not planning pregnancy in the near term, with ASCVD risk high enough to warrant a statin.

Women Who Should Consider Adding Inclisiran

You are on maximally tolerated atorvastatin (or the highest dose you can take without muscle symptoms) and LDL remains above your individualized target. You have already tried ezetimibe and LDL is still not at goal, or you cannot tolerate ezetimibe. You have established CVHD or heterozygous familial hypercholesterolemia. You are post-menopausal and adherence to daily pills has been a documented challenge.

Women Who Should Consider Switching to Inclisiran Monotherapy

You have a confirmed diagnosis of statin intolerance (creatine kinase-confirmed or multiple failed statin trials) and need significant LDL lowering. In this scenario, inclisiran without a background statin still reduces LDL by approximately 40 percent, though combined therapy achieves the largest reductions.

Women Who Should Not Use Either Drug Right Now

You are pregnant, trying to conceive, or breastfeeding. You have active liver disease (both drugs require hepatic function for their mechanism). If your LDL is mildly elevated and 10-year ASCVD risk is <5 percent, lifestyle optimization should come before starting any lipid-lowering drug.

Practical Considerations: Cost, Access, and the Twice-Yearly Injection

Atorvastatin is available as a generic and costs $4-$10 per month at major pharmacies. Inclisiran's list price in the United States is approximately $3,250 per injection ($6,500 per year). Prior authorization is required by virtually every insurer in 2025. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous FH, as an adjunct to diet and maximally tolerated statin therapy.

The administration model is also different. Every inclisiran injection is given in a clinical setting, which removes adherence burden but adds the need for scheduled office visits. For women in perimenopause or post-menopause who are already seeing their provider regularly, this may integrate well. For younger women with busy schedules, two guaranteed appointments per year may actually be easier to manage than daily pill-taking.

Switching Lipitor to Leqvio: The Practical Steps

If you and your clinician agree that switching from atorvastatin to inclisiran (or adding inclisiran) is appropriate, here is what the transition typically looks like.

First, confirm the indication. Inclisiran requires a qualifying diagnosis: established CVHD, HeFH, or high cardiovascular risk with inadequate LDL control. Your LDL must be documented above goal on maximally tolerated statin.

Second, complete prior authorization. Your provider will submit documentation of your current LDL, your statin dose, any intolerance history, and your risk category. This process takes 2-6 weeks at most insurers.

Third, schedule the first injection at your provider's office. A baseline LDL is drawn at the same visit. The second injection is scheduled at day 90, and then every 6 months thereafter.

Fourth, if you are continuing a background statin at a lower dose for tolerability, do not stop it without guidance. The combination of a low-to-moderate dose statin plus inclisiran can achieve LDL reductions comparable to high-intensity statin monotherapy, with a better side-effect profile for women who are sensitive to myalgia.

"For women who have struggled with statin side effects for years, inclisiran changes the conversation entirely," notes Dr. Elena Vasquez, MD, WomanRx editorial board member and women's-health clinician. "It is not a replacement for statins in every case, but for the woman who has failed two or three statins because of muscle pain and still has an LDL of 130, having a twice-yearly injectable option that bypasses the muscle pathway is a real clinical advance."

Monitoring on Each Drug

On atorvastatin, check a fasting lipid panel 6-8 weeks after starting or changing dose, then annually once stable. Check liver enzymes (ALT/AST) at baseline. Routine creatine kinase monitoring is not recommended unless you develop muscle symptoms. For women with PCOS or prediabetes, check HbA1c annually.

On inclisiran, a lipid panel at approximately 3 months after each injection captures near-trough response. The LDL nadir occurs around day 150-180 post-injection, and trough levels at the next injection date are the best marker of sustained efficacy. No routine liver enzyme or creatine kinase monitoring is required based on current trial data.